Comparison of Treatment Adherence in Patients Initiated on Lisdexamfetamine Dimesylate (LDX) Vs. Other Medications for the Treatment of ADHD: A Retrospective Study

Friday, October 21, 2011

Juliana Setyawan, M.S., Pharm.D., Shire Pharmaceuticals Inc, Wayne, PA

Paul Hodgkins, Ph.D., Shire Pharmaceuticals Inc., Wayne, PA

Eric Q. Wu, Ph.D., Analysis Group Inc., Boston, MA

Annie Guerin, M.S., Analysis Group Inc., Boston, MA

Genevieve Gauthier, M.S., Analysis Group Inc., Boston, MA

Martin Cloutier, M.S., Analysis Group Inc., Boston, MA

M. Haim Erder, Ph.D., Shire Pharmaceuticals Inc., Wayne, PA


Please note that this schedule is subject to change. The Program Book distributed at the Annual Meeting will have final information on dates, times, and speakers for each presentation.

New Research Poster Presentation 4.24 Comparison of Treatment Adherence in Patients Initiated on Lisdexamfetamine Dimesylate (LDX) Vs. Other Medications for the Treatment of ADHD: A Retrospective Study